Drugs maker Cipla on Tuesday said it has pledged Rs 25 crore to support government in combating the coronavirus pandemic.
This includes a voluntary donation of around Rs 3 crore from Cipla employees who have stepped forward in this hour of national need, the drug maker said in a regulatory filing.
As part of Rs 25 crore, the company has announced a donation of Rs 9 crore to the PM-CARES Fund, it added.
In addition, the company has announced a donation of Rs 8 crore to various state authorities, Cipla said.
"These contributions will help to further several immediate and long-term relief efforts that the country needs to combat the size and scale of the crisis it is confronted with," it added.
Besides, Cipla Foundation, the social responsibility arm of Cipla, has committed Rs 4 crore towards COVID response programmes, many of which are already underway, the drugs maker said.
The company said it has also allocated Rs 4 crore towards the supply of essentials including medicines, personal protective equipment, sanitisers, masks, gloves and food.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
